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Abstract
Introduction Metabolome analysis is complicated by the
continuous dynamic changes of metabolites in vivo and
ex vivo. One of the main challenges in metabolomics is the
robustness and reproducibility of results, partially driven
by pre-analytical variations.
Objectives The objective of this study was to analyse the
impact of pre-centrifugation time and temperature, and to
determine a quality control marker in plasma samples.
Methods Plasma metabolites were measured by gas
chromatography-mass spectrometry (GC–MS) and anal-
ysed with the MetaboliteDetector software. The metabo-
lites, which were the most labile to pre-analytical
variations, were further measured by enzymatic assays. A
score was calculated for their use as quality control
markers.
Results The pre-centrifugation temperature was shown to
be critical in the stability of plasma samples and had a
significant impact on metabolite concentration profiles. In
contrast, pre-centrifugation delay had only a minor impact.
Based on the results of this study, whole blood should be
kept on wet ice and centrifuged within maximum 3 h as a
prerequisite for preparing EDTA plasma samples fit for the
purpose of metabolome analysis.
Conclusions We have established a novel blood sample
quality control marker, the LacaScore, based on the
ascorbic acid to lactic acid ratio in plasma, which can be
used as an indicator of the blood pre-centrifugation con-
ditions, and hence the suitability of the sample for meta-
bolome analyses. This method can be applied in research
institutes and biobanks, enabling assessment of the quality
of their plasma sample collections.
Keywords GC/MS  Metabolomics  Plasma processing 
Pre-analytics  Biobank  Quality control
1 Introduction
Sample collection and processing for research are not
always performed in a strictly standardized manner. Bio-
logical samples are sensitive to molecular and/or environ-
mental stress and are often not handled with the optimal
precautions, generating an urgent need for validated sample
processing methods and quality control, especially in the
scope of ‘‘-omics’’ analyses (Balasubramanian et al. 2010).
In order to support the need for evidence-based protocols, a
series of sample processing method validation studies have
been published (Ammerlaan et al. 2014a, b). In addition,
biobanks and research institutes are facing the problem that
quality and the fitness-for-purpose of a given legacy
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sample is often not known, resulting in research projects
being highly error-prone (Moore et al. 2011). For
prospective collections, the workflow should thus be rig-
orously defined and validated for fitness-for-purpose. For
legacy collections of unknown pre-analytical history,
quality controls must be developed and applied.
Metabolome analysis is complicated by continuous and
dynamic changes of metabolite concentrations. Studying
metabolites, small intermediates of thousands of enzyme-
catalysed biochemical reactions, is a critical part of the
field of metabolomics. Metabolites connect different intra-
and extracellular metabolic pathways, and ensure home-
ostasis (Wishart et al. 2007). The metabolome, the total set
of metabolites, is considered to be a final phenotype, based
on the combinatorial effects of the genome, transcriptome,
proteome and environment. Metabolome analyses may thus
provide the most sensitive approach for detecting cellular
and environmental changes. Many metabolites have a very
limited half-life as they are constantly produced and
degraded by biochemical reactions (Villas-Boas et al.
2005). This property complicates metabolite analyses in a
time-limiting manner, highlighting the need for rapid
sample processing, as well as rapid quenching and accurate
metabolite measurement methods.
The plasma metabolome is subject to in vivo pre-ana-
lytical variations, related to race (Gavaghan McKee et al.
2006), sex and age (Kochhar et al. 2006), intestinal flora
(Phipps et al. 1998), circadian rhythms and the oestrous
cycle (Bollard et al. 2001), as well as diet and lifestyle
(Lenz et al. 2004). The impact of in vitro pre-analytical
variations on metabolomics data has recently been inves-
tigated on nuclear magnetic resonance (NMR) and liquid
chromatography–mass spectrometry (LC–MS) analytical
platforms (Bernini et al. 2011; Fliniaux et al. 2011; Kam-
lage et al. 2014; Yin et al. 2013).
In this study, we analysed the impact of pre-analytical
variations, i.e. pre-centrifugation time and temperature, on
the plasma metabolome. In a first phase, sensitive non-
targeted GC–MS analysis was applied as a discovery tool.
In a second phase, specific targeted enzymatic assays for
the metabolites of interest were applied. Based on these
findings, we established a novel sample quality control tool
for the ‘‘diagnosis’’ of the quality of a given plasma sample
with respect to pre-centrifugation conditions.
2 Materials and methods
2.1 Study design
Initially, the effects of pre-centrifugation storage temper-
ature (4 C) versus room temperature (RT; 18–23 C), and
pre-centrifugation delay (10, 30, and 60 min) on metabolite
concentrations in blood samples from three healthy vol-
unteers were determined using GC–MS.
Based on the outcome of this, a second part of the study
was initiated, evaluating lactic acid and ascorbic acid
concentrations using enzymatic assays in plasma samples
from a second cohort of ten healthy volunteers collected
with a range of pre-centrifugation delays (30 min, 3 h, or
23 h) at 4 C and RT. For this,10 mL blood samples from
ten healthy donors were collected in K2EDTA collection
tubes (BD #367525) and stored at RT or on ice for pre-
centrifugation delays of 30 min, 3 h, or 23 h.
These data were used to determine a ‘‘LacaScore’’ and a
LacaScore threshold, which was established using ROC
analysis. This threshold and the LacaScore’s performance
were validated in plasma samples from three independent
collections from three different institutes: (1) samples from
25 donors from different, previously constituted, IBBL
collections, with a range of blinded pre-centrifugation
delays at RT, (2) samples from 16 donors collected and
processed at the Geneva University Hospitals Biobank,
with a range of pre-centrifugation delays (30 min, 3 h, or
23 h) at 4 C and RT, (3) samples from 20 donors, col-
lected and processed at the Jena University Hospital, with a
range of pre-centrifugation delays (30 min, 1, 2, 4 h) at
RT. A final analysis of ‘‘extreme’’ conditions was per-
formed in blood samples from a cohort of five healthy
donors collected immediately post-exercise with a range of
pre-centrifugation delays (1, 2, 3, 4, or 6 h) at 4 C and RT.
2.2 Plasma processing
All blood sample donors have signed informed consent
forms and the study was approved by ethics committees
(CNER approval #201107/02 for IBBL, CEREH approval
#13-203 for Geneva University Hospital and #3921-11/13
for Jena University Hospital).
For the GC–MS analysis, 10 mL blood samples were
collected from three healthy volunteers in K2EDTA 10 mL
tubes (BD #367525) and centrifuged for 10 min at 4 C,
20009g, brake five (soft). The supernatant was then ali-
quoted (10 9 200 ll aliquots per condition) and stored at
-80 C until metabolite extraction. The study was divided
into two parts: analysis of the impact of the (1) processing
temperature and (2) processing time on metabolomics data.
For (1), two processing temperatures were tested: wet ice
(4 C) and RT (18–23 C). For (2), pre-centrifugation
delays of 10, 30, and 60 min were tested.
For the targeted enzymatic assays, 10 mL blood samples
were collected in K2EDTA 10 mL tubes (BD #367525)
and centrifuged for 20 min at RT, 20009g, brake five
(soft). The supernatant was then aliquoted and stored at
-80 C until testing (IBBL and Geneva University
Hospital). Moreover, 2.7 mL blood samples were collected
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in K3EDTA tubes (Sarstedt #05.1167.001) and centrifuged
at 25009g for 10 min at 20 C. The supernatant was then
aliquoted and stored at -80 C until testing (Jena
University Hospital).
2.3 Metabolite extraction
Each plasma sample was extracted in triplicate. In addition,
plasma pools were produced by mixing an equal amount of
each sample. For each replicate, 5 lL of plasma sample
were mixed with 45 lL ice–cold methanol–water mix
(MeOH/H2O; 8/1; v/v) and vortexed on a shaking device
for 5 min at 4 C. The mix was directly centrifuged at
16,0009g for 5 min at 4 C (Eppendorf 5415R), then 30
lL supernatant was transferred into GC glass vials and
completely dried by a refrigerated CentriVap Concentrator
(Labconco) at -4 C for 40 min. To avoid condensation on
the vials, the CentriVap Concentrator was allowed to warm
to RT for 30 min prior to taking out the vials.
2.4 Gas chromatography–mass spectrometry (GC–
MS)
GC–MS measurements were performed on an Agilent 6890
gas chromatograph equipped with a DB-35MS capillary
column. The GC is coupled to an Agilent 5975C MS
equipped with an electron impact (EI) ionization source
operating at 70 eV. The mass spectrometer source was
heated to 230 C and the quadrupole to 150 C.
Metabolite derivatization was performed using a Gerstel
Multipurpose Sampler. Dried metabolite extracts in GC
glass vials were mixed with 15 lL of 2 % methoxyamine
hydrochloride in pyridine (MOX, Sigma Aldrich) and
incubated at 40 C. After 30 min, 15 lL of MSTFA (2,2,2-
trifluoro-N-methyl-N-trimethylsilyl-acetamide, Machery
Nagel) was added and the mixture was further incubated
for 30 min at 40 C.
The detector was operated in scan mode and 1 lL of
derivatized sample was injected in the GC sample inlet.
The injection was set to splitless mode and helium was
used as the carrier gas (flow rate: 1 mL/min). The GC oven
was maintained at 80 C for 6 min, then increased to
300 C (heating rate: 6 C/min). Thereafter, the tempera-
ture was increased to 325 C for 4 min (heating rate:
10 C/min). The run of one sample took 1 h.
GC–MS raw data were calibrated using the Metabo-
liteDetector software (Hiller et al. 2009) retention index
calibration option. Batch quantification (non-targeted
analysis) was performed to obtain quantitative data for
statistical analysis by multivariate ANOVA. The level of
significance was set to p\ 0.05. With our GC–MS
instrumentation, we detected ascorbic acid levels, but not
dehydroascorbic acid.
2.5 Enzymatic assays
Ascorbic acid and lactic acid levels were quantified in the
plasma by enzymatic assays (EnzyChrom Ascorbic Acid
Assay Kit, BioAssay Systems, EASC-100; L-Lactate
Assay Kit, Abcam, ab65331). All samples were measured
in duplicate. With the enzymatic assay, we detected
ascorbic acid levels, but not dehydroascorbic acid.
The manufacturer’s protocol was followed for lactic
acid quantification, using 3 lL plasma samples. Colori-
metric measurement was performed by a microplate reader
at OD450.
The ascorbic acid quantification protocol was adapted to
enable the measurement of low ascorbic acid concentra-
tions. A total of 50 lL of plasma was mixed with 50 lL
reaction mix and incubated for 10 min at RT in the dark.
Fluorimetric measurements were performed by a micro-
plate reader at kex = 530 nm and kem = 585 nm.
These enzymatic assays were also performed using 25
independently-collected, plasma samples from IBBL col-
lections with a range of blinded pre-centrifugation delay and
temperature storage conditions, 94 plasma samples from
Geneva University Hospitals Biobank collections and 80
plasma samples from Jena University Hospital. In addition,
to determine whether our findings were robust against high
lactic acid and ascorbic acid baseline levels, we sampled
blood from five healthy donors, immediately after a half-
marathon run (21 km). For each donor, blood samples were
collected and stored on ice or at RT for 1, 2, 3, 4, or 6 h. One
runner (D3) took 2 g ascorbic acid in the evening preceding
the run. Due to the extreme lactic acid and ascorbic acid
levels, the sample dilution factors in the assays were adapted.
For lactic acid quantification, plasma was diluted 1:2 in assay
buffer, and for ascorbic acid quantification, plasma was
diluted 1:3 in milliQ water before quantification according to
the recommendation of the manufacturers.
Lactic acid and ascorbic acid concentration values were
used for LacaScore calculation: for each sample, the
ascorbic acid level was divided by the corresponding lactic
acid level and multiplied by 105 (LacaScore = ascorbate
[lM]/lactate [lM] 9 105).
2.6 ROC analysis
Based on the data of the 10 enzymatic assay donors, we
established a LacaScore threshold by ROC analysis. As a
decision threshold, plasma samples considered ‘‘high pre-
centrifugation quality’’ (or ‘‘positive’’) were qualified as those
extracted from blood stored either at 4 C for up to 3 h or at
RT for up to 2 h before centrifugation (Fig. 1). The remaining
plasma samples were qualified as ‘‘low pre-centrifugation
quality’’ (or ‘‘negative’’). The ROC analysis was performed in
R 3.2.2 using the pROC package (Robin et al. 2011).
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3 Results
In this study, we aimed to identify markers for the
assessment of the quality of plasma sample collections in
biobanks and research institutes. We analysed the impact of
two pre-analytical conditions on plasma sample metabo-
lites: pre-centrifugation delay and temperature.
3.1 Significant impact of pre-analytical factors
on the plasma metabolome
In a first step, we compared the metabolomics signature of
plasma samples obtained from three healthy donors. For
each donor, we collected blood into two K2EDTA blood
collection tubes which we immediately stored on wet ice or
RT. For each condition, we stored the tubes for 10, 30 and
60 min before plasma processing, such delays being in
accordance with previously published recommendations
(Fliniaux et al. 2011; Bernini et al. 2011; Kamlage et al.
2014; Yin et al. 2013).
MANOVA analysis of GC–MS analysed samples
revealed that for the 1 h time course applied in this
experiment, the pre-centrifugation time had a minor impact
whereas the storage temperature had a significant impact
on the plasma metabolome. Only 3 out of 236 (*1.3 %)
detected metabolites were significantly increased over the
1 h time course: RI 1035.67, RI 1614.13 and RI 1573.94
(p = 0.008, p = 0.033 and p = 0.049, respectively). These
metabolites could not be identified by our in-house com-
pound library and are therefore presented as their respec-
tive retention indices (RI).
In contrast to the pre-centrifugation delay, the storage
temperature had a significant impact on the levels of 48 out
of the 236 (20.3 %) detected metabolites (Table 1, sup-
plementary Data 1). Three metabolites showed a false
discovery rate (FDR) \0.05 after correction for multiple
testing. Lactic acid levels were significantly higher in
samples stored at RT compared to the wet ice stored
samples (FDR = 0.001). Ascorbic acid and RI 1809.71
levels were significantly lower at RT compared to 4 C
(FDR = 0.003 and FDR = 0.004, respectively).
3.2 LacaScore for plasma quality assessment
Having established that lactic acid and ascorbic acid are the
most temperature-sensitive metabolites, we then extended
the pre-centrifugation time period beyond 60 min. Two
further time points were chosen. The first, based on pub-
lished recommendations for metabolomics (Yin et al. 2013;
Bernini et al. 2011), was at 3 h, corresponding to a critical
time for compatibility with analyses which are sensitive to
pre-centrifugation conditions. The second was 23 h, chosen
as a time point at which it is certain that the sample quality
for sensitive analyses is compromised.
As GC–MS instruments are not routinely operated in
biobanks and research institutes, we quantified lactic acid
and ascorbic acid levels using largely accessible enzymatic
assays. We calculated the ratio of ascorbic acid to lactic
acid for each sample and multiplied this ratio by 105,
hereafter termed the ‘‘LacaScore’’.
The LacaScore decreased over time between 30 min and
3 h at both 4 C and RT (Fig. 2), due to a decrease of
ascorbic acid and an increase of lactic acid levels (Sup-
plementary Data 2). A significant difference of the
LacaScore was observed between 4 C and RT stored
samples after a 30-min pre-centrifugation delay, validating
our findings from the GC–MS study. All samples from
donors #8 and #9 showed very low initial ascorbic acid
levels and could not be quantified by the enzymatic assay
(below the limit of quantification of the method). There-
fore, the LacaScore for all these samples was set to 0.
3.3 LacaScore threshold and validation
in independent–datasets
Based on the data from the ten donors we calculated a
LacaScore diagnostic threshold. We qualified as ‘‘high pre-
centrifugation quality’’ all samples stored either on ice for
up to 3 h or at RT (18–23 C) for less than 3 h. As ‘‘low
pre-centrifugation quality’’, we defined all samples stored
longer than 3 h on ice, or 3 h or longer at RT. The ROC
analysis based on the LacaScore data from the ten donors
Time of 
collection
RT
0.5 1 2 3
4°C
12 23
pre-centrifugation delay [h]
0.5 1 2 3 12 23
pre-centrifugation delay [h]
Fig.1 Representation of ranges
of pre-analytical conditions, at
RT and 4 C, corresponding to
‘‘high pre-centrifugation
quality’’ or ‘‘positive’’ samples
(green) and ‘‘low pre-
centrifugation quality’’ or
‘‘negative’’ samples (red)
(Color figure online)
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showed an optimal LacaScore threshold of 5.2 with
specificity = 0.967 and sensitivity = 0.633 (Fig. 3).
To validate the LacaScore threshold, we used a blinded
set of 25 plasma samples collected at RT with a range of
pre-centrifugation delays. Based on the threshold of
LacaScore 5.2, the diagnostic accuracy was 68 %. When
we assigned samples with LacaScore between 5.2 and 52 to
a category qualified as ‘‘indeterminate’’, and included the
samples of ‘‘indeterminate’’ quality status among the
accurately diagnosed ones, the diagnostic accuracy
increased to 88 % (Table 2), and this was selected as the
final algorithm. With these settings, LacaScore \5.2 cor-
responds to EDTA plasma samples with pre-analytical
quality equivalent to either \3 h RT or B3 h 4 C pre-
centrifugation delay, LacaScore[52 corresponds to EDTA
plasma samples with pre-analytical quality equivalent to
C3 h RT or [3 h 4 C pre-centrifugation delay (Fig. 1),
while 5.2 B LacaScore B 52 corresponds to indeterminate
Table 1 The impact of storage temperature prior to centrifugation on the metabolic profile in plasma
Metabolite RTa (mean ± SD) Icea (mean ± SD) Fold change (RT vs. Ice) P** Adjusted p (Benjamini & Hochberg)
Ascorbic acid 1.717 ± 1.043 16.572 ± 5.979 0.104 \0.001 0.003
Carbonic acid 1.445 ± 0.385 2.026 ± 0.209 0.713 0.003 0.155
RI 1809.71 3.877 ± 0.492 4.646 ± 0.383 0.835 \0.001 0.004
RI 1193.68 1.398 ± 0.098 1.604 ± 0.320 0.871 0.006 0.182
RI 1441.25 1.069 ± 0.080 1.133 ± 0.059 0.943 0.007 0.182
RI 1027.62 1.141 ± 0.255 1.097 ± 0.454 1.040 0.005 0.173
RI 1056.57 1.135 ± 0.800 1.081 ± 0.470 1.050 0.002 0.125
RI 3088.55 1.139 ± 0.148 1.084 ± 0.314 1.051 0.012 0.182
RI 1132.34 1.129 ± 0.048 1.056 ± 0.040 1.069 0.004 0.161
Lactic acid 1.649 ± 0.185 1.055 ± 0.141 1.563 \0.001 0.001
a Normalized peak intensities
** Computed by MANOVA, level of significance p\ 0.05
Significant metabolic changes observed in concentrations of the 236 detected metabolites when comparing room temperature (RT) and ice-stored
(Ice) blood samples for the 60 min time course. The top ten metabolites are shown. The complete list can be seen in Supplementary Data 1
L
ac
aS
co
re
0
50
100
150
200
250
300
350
Time (h)
3222123210
D1 RT D1 Ice
D2 RT D2 Ice
D3 RT D3 Ice
D4 RT D4 Ice
D5 RT D5 Ice
D6 RT D6 Ice
D7 RT D7 Ice
D8 RT D8 Ice
D9 RT D9 Ice
D10 RT D10 Ice
Fig.2 LacaScore showing significant differences due to pre-analyt-
ical conditions. The LacaScore is found to be higher in samples stored
on ice (dashed lines) compared to samples stored at room temperature
(solid lines). D1–D10 Donor 1-Donor10; RT room temperature
storage (18–23 C); Ice Ice storage (4 C)
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pre-analytical quality. Application of this algorithm to the
two other plasma collections from Geneva University
Hospitals and from Jena University Hospital gave diag-
nostic accuracies of 71 and 86 % respectively (Table 3).
The detailed results from these collections are presented in
Supplementary Data 3 and 4.
3.4 Impact of extreme in vivo conditions
on LacaScore
To evaluate the impact of high baseline lactic acid con-
centrations on the LacaScore, we collected blood from five
healthy donors after a half-marathon. One of them had
ingested a commercially available 2 g ascorbic acid tablet
on the day preceding the half-marathon. For each donor,
blood samples were collected and stored on ice or at RT for
1, 2, 3, 4, and 6 h and the quality of the sample according
to the LacaScore algorithm was determined (Supplemen-
tary Data 5). The high lactic acid and ascorbic acid baseline
concentrations had an impact on the LacaScore diagnostic
accuracy for sample quality and fitness-for-purpose, with a
reduction in accuracy (57 %).
4 Discussion
Pre-analytical variations should not be neglected in any ‘‘-
omics’’ biomarker discovery research project since the pre-
analytical factors are the major source for inappropriate or
inconsistent sample quality. Specimen processing should
be conducted in a standardized way, especially when more
than two biobanks or research institutes are involved.
Among all ‘‘-omics’’ analyses, metabolomics is one of
the most sensitive to pre-analytical variations. Repro-
ducibility and reliability of the analytical data can be
increased by sample processing method validation and
assessment of significant changes resulting from non-s-
tandardized sample handling. We have previously pub-
lished an EDTA, RT/20009g centrifugation plasma
processing method validation (Ammerlaan et al. 2014a).
EDTA plasma is the most commonly collected plasma type
and also the most frequently used in metabolomics analy-
ses. We reported that the method is reproducible, robust to
centrifugation temperature and centrifugation brake con-
ditions, with only 2–4 % of the GC–MS-detected
metabolites being significantly modified under different
conditions (Ammerlaan et al. 2014a). The robustness to
different pre-centrifugation conditions on plasma GC–MS
metabolomics was addressed in the present study.
4.1 Impact of pre-analytical conditions on plasma
metabolites
The results of this study show that the temperature at which
blood samples are kept between the time of collection and
the time of centrifugation and separation of the plasma
from the blood cells is crucial for the plasma metabolomics
data outcome. The levels of 48 out of 236 detected
metabolites (20.3 %) were significantly altered when
comparing blood samples stored at RT with ice-stored
samples. Many standard operating procedures do not use
ice for blood collection. However, for metabolomics
applications, sample processing on ice is crucial and doc-
umentation of the critical pre-analytical steps in a Standard
PREanalytical Code (SPREC) is recommended (Betsou
et al. 2010; Bervoets et al. 2015). Two known metabolites,
ascorbic acid and lactic acid, showed the highest temper-
ature-dependent instability and we have demonstrated that
their ratio can be used as quality control marker for plasma
sample quality evaluation.
In humans, ascorbic acid needs to be provided in the diet
and L-ascorbic acid (LAA) is oxidized to dehydroascorbic
acid (DHAA) after exposure to high temperature, pH, light,
oxygen or metals, and irreversible hydrolysis of DHAA
leads to by-products such as oxalic acid, L-threonic acid or
L-xylose (Spı´nola et al. 2014). A recent ascorbic acid sta-
bility study showed that ascorbic acid levels were signifi-
cantly reduced in human blood plasma stored at RT
compared to storage on ice, which is in accordance with the
results presented in this study (Karlsen et al. 2007).
A marked loss of ascorbic acid in EDTA plasma within
30 min of blood collection was previously reported at RT
Specificity
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1.0 0.8 0.6 0.4 0.2 0.0
Fig.3 ROC curve for the determination of an optimal decision
threshold (AUC = 0.794). The ROC analysis was performed on the
LacaScores calculated on the enzymatic assay results based on 10
healthy donors. High pre-centrifugation quality samples were con-
sidered as ‘‘positive’’. At a LacaScore threshold of 5.2, a specificity of
0.967 and a sensitivity of 0.633 were obtained
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Table 2 Quality diagnosis based on the LacaScore determined from 25 independent biobank plasma samples with various pre-centrifugation
delays at room temperature
Sample Pre-centrifugation delay at RT (h) Pre-centrifugation quality LacaScore Diagnosed pre-centrifugation qualitya
S1 6:10 Low 0.000 Low
S2 7:36 Low 0.000 Low
S3 3:30 Low 0.000 Low
S4 4:52 Low 54.436 High
S5 2:30 High 11.475 Indeterminate
S6 5:35 Low 0.000 Low
S7 6:25 Low 51.388 Indeterminate
S8 3:47 Low 11.130 Indeterminate
S9 7:00 Low 0.000 Low
S10 6:00 Low 0.000 Low
S11 3:40 Low 0.000 Low
S12 5:55 Low 40.896 Indeterminate
S13 4:20 Low 0.000 Low
S14 2:54 High 137.956 High
S15 6:27 Low 0.000 Low
S16 1:50 High 618.312 High
S17 0:52 High 104.279 High
S18 0:52 High 0.000 Low
S19 2:42 High 236.286 High
S20 7:30 Low 34.784 Indeterminate
S21 7:40 Low 0.000 Low
S22 9:56 Low 0.000 Low
S23 3:22 Low 82.012 High
S24 2:16 High 190.559 High
S25 3:54 Low 9.303 Indeterminate
a LacaScore[ 52: high pre-centrifugation quality; LacaScore\ 5.2: low pre-centrifugation quality; 5.2 B LacaScore B 52: indeterminate
quality; diagnostic accuracy: 88 % RT room temperature storage (18–23 C)
Table 3 Quality diagnosis based on the LacaScore determined from 36 independent biobank plasma samples with various pre-centrifugation
delays at room temperature or 4 C
Temperature Time (h) Pre-centrifugation quality LacaScore range [min–max] Correctly diagnosed samples
Geneva University Hospital collection (n = 16)
RT 0.5 High [0–1487.41] 5 out of 16
RT 3 Low [0–1311.70] 13 out of 15
RT 23 Low [0–6.67] 16 out of 16
4 C 0.5 High [0–1314.18] 10 out of 16
4 C 3 High [0–547.76] 8 out of 15
4 C 23 Low [0–93.46] 15 out of 16
Jena University Hospital collection (n = 20)
RT 0.5 High [0–4747.87] 19 out of 20
RT 1 High [2.25–1636.05] 19 out of 20
RT 2 High [0–1336.42] 19 out of 20
RT 4 Low [0–655.67] 12 out of 20
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(Chung et al. 2001), and another study showed plasma
ascorbic acid was stable when blood was stored for up to
6 h at 4 C (Margolis et al. 1991). EDTA vacutainers have
been shown to be superior to other types of vacutainers in
maintaining low ex vivo oxidation of ascorbic acid (Lyk-
kesfeldt 2012). Degradation of ascorbic acid may be due to
oxidation and/or transformation to oxalate (Wilson and
Liedtke 1991). This degradation may occur in the plasma
sample itself, and it has been shown that ascorbic acid is
stable in samples extracted with meta-phosphoric acid and
placed on a cool autosampler for at least 10 h (Kand’ar and
Zakova 2008). Low temperature is a key factor in pre-
venting the oxidation of LAA and related studies indicate
stability at -80 C (Spı´nola et al. 2014). However, because
of potential residual enzymatic activities and instability
over very long-term -80 C storage, cryopreservation in
liquid nitrogen is preferred in the scope of metabolomics
analyses. This had already been suggested in 2005 by the
EPIC consortium who had shown that ascorbic acid can be
reliably measured in plasma samples stored in liquid
nitrogen for long periods without any stabilizing agents
(Jenab et al. 2005).
In contrast to decreased ascorbic acid levels, lactic acid
levels were significantly higher in plasma from blood
samples kept at RT compared to blood samples stored on
ice. The significant changes of lactic acid can be explained
by anaerobic reactions that occur over time. When col-
lecting a sample via venepuncture, low oxygen venous
blood is drawn into a vacuum container. Aerobic reactions
from blood cells other than red blood cells, such as plate-
lets and white blood cells, rapidly consume the remaining
oxygen inside the collected blood sample. At RT the
enzymatic reactions occur faster than at 4 C and the
oxygen depletion is much faster. This probably leads to a
shift into anaerobic energy production, such as lactic acid
production. Furthermore, erythrocytes, the most abundant
cells present in the blood, do not have any organelles, such
as mitochondria. Therefore, energy production is only
performed via glycolysis, leading to lactic acid production.
Lactic acid rapidly accumulates in the cells and is excreted
into the plasma by either monocarboxylate transport sys-
tems or non-ionic diffusion (Simchowitz and Textor 1992;
De Bruijne et al. 1983). These enzymatic reactions are
slowed down at lower temperatures.
Recently, it has been shown that lactic acid levels were
significantly higher in whole blood samples stored at RT
for 30 min compared to whole blood samples stored on ice
(Seymour et al. 2011). In similar studies, NMR measure-
ments showed that lactic acid levels are increased in
samples processed at RT for pre-centrifugation delays of 4
and 24 h. In accordance with the results obtained in this
study, this increase was not observed when samples were
stored on ice (Fliniaux et al. 2011). In conclusion, EDTA
plasma samples are stable and fit-for-purpose for metabo-
lomic analyses after 30 min blood pre-centrifugation delay
at RT.
4.2 LacaScore
In this study, we propose a novel plasma sample quality
marker based on the ratio of ascorbic acid to lactic acid, the
LacaScore. Recently, a review was published on potential
quality control tools for different types of biospecimens
and different types of pre-analytical variations, and ascor-
bic acid was identified as one of the top quality control
marker candidates (Betsou et al. 2013). The reference
ranges of ascorbic acid in the general population are
44.9–76.7 lM (Lentner 1981), whereas ascorbic acid
concentration in plasma has been reported to be around
134 lM after oral administration of 1–2 g vitamin C
(Spı´nola et al. 2014). The reference ranges of lactate in the
general population are 740–2400 lM (Lentner 1981).
Therefore, the reference range for the LacaScore (ascorbic
acid to lactic acid ratio multiplied by 105) is between 1871
and 10,365. Prolonged pre-centrifugation delay at RT
decreases this ratio. More specifically, based on the results
of this study, after 3 h at RT, the range for ascorbic acid in
plasma will be 0–2 lM, while the range for lactate will be
2520–4849 lM (Supplementary Data 1). The LacaScore
will therefore be between 0 and 79.37. A LacaScore lower
than 5.2 indicates the blood sample has a pre-centrifugation
delay of at least 3 h at RT and plasma samples unfit for
metabolomics applications.
We conducted two studies to validate the LacaScore as a
quality control marker. First, our method was applied to
three independent plasma sample collections: a blinded
dataset of 25 previously collected plasma samples (Lux-
embourg), giving a diagnostic accuracy of 88 %, a dataset
of independently collected plasma samples from 16 donors
(Geneva), giving a diagnostic accuracy of 71 % and a
dataset of independently collected plasma samples from 20
donors (Jena), giving a diagnostic accuracy of 86 %. Pre-
diction accuracy might increase with the use of a larger
sample size for calculating the LacaScore decision
threshold. Second, we investigated the impact of extreme
ascorbic acid and lactic acid concentrations on the
LacaScore diagnostic accuracy. Abnormal ascorbic acid
concentrations have been shown to be associated with
diseases, such as stroke and acute pancreatitis (Sanchez-
Moreno et al. 2004; Scott et al. 1993). In addition, ascorbic
acid supplementation greatly impacts the measured levels
in blood by doubling or tripling its blood concentration
(Padayatty et al. 2004). Physical exercise has not only been
shown to cause high lactic acid levels but also a transient
increase in circulating ascorbic acid (Peake 2003). We
suspect that the LacaScore might not be applicable in cases
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of hyperoxalaemia (with very low ascorbic acid levels,
6.5 ± 18.6 lM) (Lentner 1981) or in cases of acute etha-
nolaemia (with very high lactate levels,
3500 ± 4300 lM) (Lentner 1981). It has been shown that
plasma lactate levels increase by 2–12 times after running,
due to production of lactate by skeletal muscles (Kondoh
et al. 1992). In blood samples collected from runners after a
semi-marathon, diagnostic accuracy was reduced to 57 %
due to high concentrations of ascorbic acid and lactic acid.
Therefore, to guarantee a proper sample quality evaluation,
we recommend avoiding the use of the LacaScore with
EDTA plasma samples from donors with extremely high
lactic acid inducing conditions, such as intensive exercise,
ethanolaemia, acute sepsis, cardiac arrest or trauma
(Trzeciak et al. 2007; Kliegel et al. 2004; Abramson et al.
1993). Since both ascorbic acid and lactic acid are present
and quantifiable in other types of biological fluids, namely
cerebrospinal fluid and urine, use of the proposed tool
might also be applicable to these types of biofluids. Con-
cerning serum and plasma sample types, we propose use of
the LacaScore with EDTA plasma. The LacaScore is not
applicable to citrate plasma in which the ascorbic acid is
stable over time (Trezzi, unpublished data) and may not be
applicable to heparinized plasma and serum in which the
ascorbic acid degradation has been shown to be slower than
in EDTA plasma (Ching et al. 2002). In summary, the
scope of application of the LacaScore is defined as the
following: EDTA plasma samples, ascorbic acid concen-
tration\ 15 lM and lactic acid concentration\ 10 mM.
When the scope of application is defined as above, the
diagnostic accuracy in the marathon runners cohort is 71 %
(Supplementary Data 5), similar to that in all the other
sample cohorts.
The reported LacaScore thresholds were calculated with
the enzymatic assays from Abcam and Bioassay Systems.
If different lactic acid and/or ascorbic acid measurement
methods are used, the LacaScore thresholds may need to be
re-calculated. In order to demonstrate this, we have mea-
sured the lactic acid concentrations in the Jena collection
samples with the Architect method and showed that the
Architect and Abcam methods are not commutable (Sup-
plementary Data 6).
Given the high specificity of 97 %, the LacaScore is an
appropriate tool for the selection of EDTA plasma samples
which must be of high pre-centrifugation quality. This
comes admittedly at the cost of a limited number of ‘‘false
negative’’ samples, samples ‘‘rejected’’ when in fact of
appropriate quality. Each biobank or research laboratory
may define its acceptance criteria for the LacaScore-‘‘in-
determinate’’ samples. The LacaScore is also suitable for
evaluating the overall quality of EDTA plasma collections.
Here again, each biobank or research laboratory may define
its acceptance criteria for the overall quality of a collection.
Finally, the LacaScore can assist researchers and biobanks
in stratifying legacy plasma samples, in the scope of
downstream analyses which are known to be sensitive to
the plasma pre-centrifugation conditions.
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